SUTU (.07) Recieves Strategic Patent for Key Features of SuperStitch and HeartStitch Technology
Market Wire "US Press Releases "
FOUNTAIN VALLEY, CALIFORNIA -- (MARKET WIRE) -- 05/23/07 -- Sutura, Inc. ("Sutura") (OTCBB: SUTU), an innovative developer of minimally invasive vascular suturing devices, announced today it is has received notice of issuance of a critical patent to add to its intellectual property portfolio. This strategic patent, which was issued to Sutura for device and method of suturing, relates to several key features of the core SuperStitch and HeartStitch technology.
Ben Brosch, V.P. of Engineering and R&D, and co-inventor of the Sutura's vascular suturing devices said, "These technical features of our SuperStitch and HeartStitch products are crucial to the reliability and functionality of the devices, and protecting these proprietary features is a priority for Sutura."
Anthony Nobles, Ph.D., Chairman and Chief Scientific Officer of Sutura stated, "Sutura is committed to building and protecting our intellectual property portfolio. We have built this company on the strength and value of our technology and every patent we receive expands and strengthens our position in the market."
Sutura has 18 issued patents for its technology in vascular, cardio-vascular and biological suturing in the US, Europe and Asia. Sutura also has several additional patents pending worldwide in these highly competitive fields.
About Sutura, Inc.
Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.
Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.
Forward-Looking Information Is Subject to Risk and Uncertainty
Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the ability of the company to raise additional funds necessary for the continued operation of the company, acceptance of the SuperStitch® and HeartStitch® devices by medical providers and the marketplace in general, the ability of the company to establish a successful strategic relationships or to complete strategic transactions with third parties, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.